Â鶹ѧÉú¾«Æ·°æ

Journal Article

1. Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM (2023). Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol, 159(5), 545-553. ()
2. Trepanowski N, Chang MS, Zhou G, Ahmad M, Berry EG, Bui K, Butler WH, Chu EY, Curiel-Lewandrowski C, Dellalana LE, Ellis DL, Freeman SC, Gorrepati PL, Grossman D, Gyurdzhyan S, Kanetsky PA, King ALO, Kolla AM, Lian CG, Lin JY, Liu V, Lowenthal A, McCoy KN, Munjal A, Myrdal CN, Perkins S, Powers JG, Rauck C, Smart TC, Stein JA, Venna S, Walsh ME, Wang JY, Leachman SA, Swetter SM, Hartman RI (2022). Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study. J Am Acad Dermatol, 87(5), 1217-1219. ()
3. Kline CD, Anderson M, Bassett JW, Kent G, Berryman R, Honeggar M, Ito S, Wakamatsu K, Indra AK, Moos PJ, Leachman SA, Cassidy PB (2022). MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. Cancers (Basel), 14(20). ()
4. Aspinwall LG, Drummond DM, Stump TK, Kohlmann WK, Leachman SA (2022). Interactive Beliefs about Genes and Behavior Predict Improved Sun Protection Following Melanoma Genetic Counseling. Ann Behav Med, 56(8), 816-829. ()
5. Carpenter EL, Wyant MB, Indra A, Ito S, Wakamatsu K, Merrill GF, Moos PJ, Cassidy PB, Leachman SA, Ganguli-Indra G, Indra AK (2022). Thioredoxin Reductase 1 Modulates Pigmentation and Photobiology of Murine Melanocytes in vivo. J Invest Dermatol, 142(7), 1903-1911.e5. ()
6. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res, 27(10), 2678-2697. ()
7. Taber JM, Aspinwall LG, Drummond DM, Stump TK, Kohlmann W, Champine M, Cassidy P, Leachman SA (2020). Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma. Ann Behav Med, 55(1), 24-40. ()
8. Fried LJ, Tan A, Berry EG, Braun RP, Curiel-Lewandrowski C, Curtis J, Ferris LK, Hartman RI, Jaimes N, Kawaoka JC, Kim CC, Lallas A, Leachman SA, Levin A, Lucey P, Marchetti MA, Marghoob AA, Miller D, Nelson KC, Prodanovic E, Seiverling EV, Swetter SM, Savory SA, Usatine RP, Wei ML, Polsky D, Stein JA, Liebman TN (2021). Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians: Results of a Modified Delphi Survey of Pigmented Lesion Experts. JAMA Dermatol, 157(2), 189-197. ()
9. Wu YP, Aspinwall LG, Parsons B, Stump TK, Nottingham K, Kohlmann W, Champine M, Cassidy P, Leachman SA (2020). Parent and child perspectives on family interactions related to melanoma risk and prevention after CDKN2A/p16 testing of minor children. J Community Genet, 11(3), 321-329. ()
10. Parsons BG, Hay JL, Aspinwall LG, Zaugg K, Zhu A, Mooney RH, Klein SZ, Grossman D, Leachman SA, Wu YP (2019). Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control. J Cancer Educ, 35(3), 509-514. ()
11. Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, DOrazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF (2019). Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. J Invest Dermatol, 140(2), 269-274. ()
12. Stump TK, Aspinwall LG, Drummond DM, Taber JM, Kohlmann W, Champine M, Cassidy PB, Petrie T, Liley B, Leachman SA (2019). CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later. Genet Med, 22(1), 26-34. ()
13. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP (2019). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psychooncology, 29(1), 148-155. ()
14. Wu YP, Parsons BG, Nagelhout E, Haaland B, Jensen J, Zaugg K, Caputo H, Lensink R, Harding G, Yancey J, Klein SZ, Leachman SA, Tercyak KP (2019). A four-group experiment to improve Western high school students' sun protection behaviors. Transl Behav Med, 9(3), 468-479. ()
15. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman SA (2019). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. Pediatr Dermatol, 36(3), 317-323. ()
16. Wu YP, Parsons BG, Mooney R, Aspinwall LG, Cloyes K, Hay JL, Kohlmann W, Grossman D, Leachman SA (2018). Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. J Community Health, 43(5), 993-1001. ()
17. Wu YP, Aspinwall LG, Nagelhout E, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Cassidy P, Leachman SA (2016). Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ, 33(4), 774-781. ()
18. Nelson KC, Grossman D, Kim CC, Chen SC, Curiel-Lewandrowski CN, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming ME (2018). Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol, 79(2), 367-369. ()
19. Stump TK, Aspinwall LG, Kohlmann W, Champine M, Hauglid J, Wu YP, Scott E, Cassidy P, Leachman SA (2018). Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress. J Genet Couns, 27(4), 955-967. ()
20. Stump TK, Aspinwall LG, Gray EL, Xu S, Maganti N, Leachman SA, Alshurafa N, Robinson JK (2018). Daily Minutes of Unprotected Sun Exposure (MUSE) Inventory: Measure description and comparisons to UVR sensor and sun protection survey data. Prev Med Rep, 11, 305-311. ()
21. Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA (2017). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns, 101(3), 452-459. ()
22. Wu YP, Kohlmann W, Curtin K, Yu Z, Hanson HA, Hashibe M, Parsons BG, Wong J, Schiffman JD, Grossman D, Leachman SA (2017). Melanoma risk assessment based on relatives' age at diagnosis. Cancer Causes Control, 29(2), 193-199. ()
23. Aspinwall LG, Stump TK, Taber JM, Drummond DM, Kohlmann W, Champine M, Leachman SA (2018). Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. Transl Behav Med, 8(1), 29-43. ()
24. Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Hiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Peri B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA, GenoMEL Study Group (2017). Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. J Invest Dermatol, 137(12), 2606-2612. ()
25. Chen LL, Zhu J, Schumacher J, Wei C, Ramdas L, Prieto VG, Jimenez A, Velasco MA, Tripp SR, Andtbacka RHI, Gouw L, Rodgers GM, Zhang L, Chan BK, Cassidy PB, Benjamin RS, Leachman SA, Frazier ML (2017). SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions. PLoS One, 12(9), e0184154. ()
26. Eroh GD, Clayton FC, Florell SR, Cassidy PB, Chirife A, Marn CF, Valenzuela LO, Campbell MS, Seger J, Rowntree VJ, Leachman SA (2017). Cellular and ultrastructural characterization of the grey-morph phenotype in southern right whales (Eubalaena australis). PLoS One, 12(2), e0171449. ()
27. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D (2016). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila), 10(1), 36-44. ()
28. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399. ()
29. Taylor NJ, Handorf EA, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarr G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Hiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer J, Peri B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA, GenoMEL Consortium (2016). Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. J Invest Dermatol, 136(5), 1066-1069. ()
30. Wu YP, Aspinwall LG, Michaelis TC, Stump T, Kohlmann WG, Leachman SA (2015). Discussion of photoprotection, screening, and risk behaviors with children and grandchildren after melanoma genetic testing. J Community Genet, 7(1), 21-31. ()
31. Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, Leachman SA, Pfeffer LM (2015). Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med, 4(12), 2012-27. ()
32. Cassidy PB, Honeggar M, Poerschke RL, White K, Florell SR, Andtbacka RH, Tross J, Anderson M, Leachman SA, Moos PJ (2015). The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. Pigment Cell Melanoma Res, 28(6), 685-95. ()
33. Aspinwall LG, Stump TK, Taber JM, Kohlmann W, Leaf SL, Leachman SA (2015). Impact of melanoma genetic test reporting on perceived control over melanoma prevention. J Behav Med, 38(5), 754-65. ()
34. Taber JM, Aspinwall LG, Stump TK, Kohlmann W, Champine M, Leachman SA (2015). Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. J Behav Med, 38(5), 740-53. ()
35. Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, Leachman SA (2014). Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med, 16(11), 846-53. ()
36. Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, Leachman SA (2013). Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall. J Genet Couns, 23(3), 421-37. ()
37. Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC (2013). Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. J Am Acad Dermatol, 70(3), 435-42. ()
38. Domyan ET, Guernsey MW, Kronenberg Z, Krishnan S, Boissy RE, Vickrey AI, Rodgers C, Cassidy P, Leachman SA, Fondon JW 3rd, Yandell M, Shapiro MD (2014). Epistatic and combinatorial effects of pigmentary gene mutations in the domestic pigeon. Curr Biol, 24(4), 459-64. ()
39. Quackenbush JF, Cassidy PB, Pfeffer LM, Boucher KM, Hawkes JE, Pfeffer SR, Kopelovich L, Leachman SA (2013). Isolation of circulating microRNAs from microvesicles found in human plasma. Methods Mol Biol, 1102, 641-53. ()
40. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA (2013). Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev, 22(10), 1687-97. ()
41. Hawkes JE, Campbell J, Garvin D, Cannon-Albright L, Cassidy P, Leachman SA (2013). Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi. Front Oncol, 3, 160. ()
42. Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Grichnik JM (2012). Survival is not the only valuable end point in melanoma screening. J Invest Dermatol, 132(5), 1332-7. ()
43. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, Leachman S, Cannon-Albright L (2012). A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet, 131(1), 77-85. ()
44. Sondak VK, Leachman SA (2011). Individualizing follow-up for patients with early-stage melanoma. J Clin Oncol, 29(35), 4606-8. ()
45. Moos PJ, Olszewski K, Honeggar M, Cassidy P, Leachman S, Woessner D, Cutler NS, Veranth JM (2011). Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics, 3(11), 1199-211. ()
46. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74. ()
47. Leaf SL, Aspinwall LG, Leachman SA (2010). God and Agency in the Era of Molecular Medicine: Religious Beliefs Predict Sun-Protection Behaviors Following Melanoma Genetic Test Reporting. Arch Psychol Relig, 32, 1-26.
48. Kadekaro AL, Leachman S, Kavanagh RJ, Swope V, Cassidy P, Supp D, Sartor M, Schwemberger S, Babcock G, Wakamatsu K, Ito S, Koshoffer A, Boissy RE, Manga P, Sturm RA, Abdel-Malek ZA (2010). Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J, 24(10), 3850-60. ()
49. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. ()
50. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H (2009). Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol, 61(4), 677.e1-14. ()
51. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA (2005). Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol, 23(28), 7168-77. ()
52. Gonzales FR, Leachman S, Norgard MV, Radolf JD, McCracken GH Jr, Evans C, Hansen EJ (1987). Cloning and expression in Escherichia coli of the gene encoding the heat-modifiable major outer membrane protein of Haemophilus influenzae type b. Infect Immun, 55(12), 2993-3000. ()

Review

1. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. [Review]. JAMA Dermatol, 156(9), 1004-1011. ()
2. Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, Leachman SA, Swetter SM (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. [Review]. Melanoma Manag, 6(4), MMT32. ()
3. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (2018). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. [Review]. Cancer, 125(1), 18-44. ()
4. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. [Review]. Melanoma Manag, 4(1), 13-37. ()
5. Wu YP, Aspinwall LG, Conn BM, Stump T, Grahmann B, Leachman SA (2016). A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. [Review]. Prev Med, 88, 153-67. ()
6. Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen SC (2014). Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. [Review]. JAMA Dermatol, 151(2), 212-8. ()
7. Leachman SA, Reed BR (2006). The use of dermatologic drugs in pregnancy and lactation. [Review]. Dermatol Clin, 24(2), 167-97, vi. ()

Editorial

1. Varedi A, Wu YP, Klein SZ, Leachman SA, Grossman D (2018). Mineral sunscreens not recommended by Consumer Reports: Suggestions to improve the review process. J Am Acad Dermatol, 80(3), 832-833. ()

Letter

1. Varedi A, Gardner LJ, Kim CC, Chu EY, Ming ME, Leachman SA, Curiel-Lewandrowski C, Swetter SM, Grossman D (2019). Use of new molecular tests for melanoma by pigmented-lesion experts. [Letter to the editor]. J Am Acad Dermatol, 82(1), 245-247. ()
2. Curtis JA, Tanner P, Hull CM, Leachman SA (2015). Reply to: "Nail curing UV lamps: Trivial exposure not cause for public alarm". [Letter to the editor]. J Am Acad Dermatol, 73(5), e187. ()
3. Taber JM, Aspinwall LG, Leaf SL, Kohlmann W, Leachman SA (2013). Partner involvement in conduct of skin self-examinations remains low following CDKN2A/p16 genetic test reporting and counseling. [Letter to the editor]. J Am Acad Dermatol, 69(5), 842-844. ()

Patent

1. Pershing LK, Leachman SA (2005). Skin Type Assessment and Nevi Screening for Skin Cancer with a Non-invasive Portable Reflectance Spectrophotometer, Patent Pending, United States. U.S. Patent No. 11-115-646. Washington, D.C.:U.S. Patent and Trademark Office.
2. Pershing LK, Leachman SA (2004). Method for Detection and Characterization of Premalignant Transformation (Markers of Melanoma Predisposition and Transformation), Patent Pending, International. U.S. Patent No. PCT/US2004/013318. Washington, D.C.:U.S. Patent and Trademark Office.

News

• Summer's Deadliest Skin Disease